Alpha Tau(US:DRTS)2025-03-12 20:02Financial Performance - Alpha Tau reported a net loss of $31.8 million, or $0.45 per share, for the year ended December 31, 2024, compared to a net loss of $29.2 million, or $0.42 per share, in 2023[10]. - Financial income, net, decreased to $4.3 million in 2024 from $6.5 million in 2023, attributed to lower income from warrant revaluation and bank deposits[9]. Research and Development - Research and development expenses increased to $27.0 million in 2024 from $26.4 million in 2023, driven by higher employee compensation and increased raw material costs[6]. - Alpha Tau achieved a systemic objective response rate of 75% and a complete response rate of 37.5% in a trial combining Alpha DaRT with Keytruda for head and neck cancer, significantly higher than historical rates of 19% and 5% respectively[4]. - The FDA approved an Investigational Device Exemption (IDE) for a U.S. pilot study of Alpha DaRT in combination with first-line chemotherapy for newly diagnosed pancreatic cancer, expanding the trial from 12 to 30 patients[4]. - The company is targeting the first patient enrollment in a pancreatic cancer pilot study in the U.S. in Q2 2025[13]. Operational Expenses - Marketing expenses rose to $2.3 million in 2024 from $1.9 million in 2023 due to increased marketing activities[7]. - General and administrative expenses decreased to $6.7 million in 2024 from $7.3 million in 2023, primarily due to lower professional fees[8]. Cash Position - The company had cash and cash equivalents of $62.9 million as of December 31, 2024, down from $84.9 million in 2023, with an expected runway of at least two years[11]. Facility Development - Alpha Tau's Hudson, NH facility is expected to complete its first phase of construction in the coming months, enhancing operational capabilities for Alpha DaRT production later in 2025[2].